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Objective: To ensure optimal care for patients with schizophrenia, antipsychotic medications 
must be appropriately prescribed and used. Therefore, the primary objectives of this study were 
to identify and describe pathways for antipsychotic prescribing, assess the consistency of 
observed pathways with treatment guidelines, and describe variability across facilities. 
Methods: Data from Veterans Affairs administrative data sets from fiscal year (FY) 2003 to FY 
2007 were gathered for analysis in this retrospective cohort study of antipsychotic prescribing 
pathways among 13 facilities across two regional networks. Patients with a new episode of care 
for schizophrenia or schizoaffective disorder in FY 2005 were identified, and antipsychotic 
prescribing history was obtained for two years before and after the index diagnosis. 
Demographic characteristics and distribution of comorbidities were assessed. Median medical 
center rates of polypharmacy were calculated and compared with Fisher’s exact test. 
Results: Of 1,923 patients with a new episode of schizophrenia care, 1,003 (52%) had complete 
data on prescribing pathways. A majority (74%) of patients were prescribed antipsychotic 
monotherapy, and 19% received antipsychotic polypharmacy. Of patients receiving antipsychotic 
polypharmacy, 65% began polypharmacy within 90 days of starting any antipsychotic treatment. 
There was a fourfold difference in polypharmacy across facilities. Antipsychotic polypharmacy 
was not associated with geographic location or medical center patient volume. Clozapine 
utilization was low (0%–2%). 
Conclusions: Retrospective examination of longitudinal prescribing patterns identified multiple 
antipsychotic prescribing pathways. Although most patients received guideline-concordant care, 
antipsychotic polypharmacy was commonly used as initial treatment, and there was substantial 
variability among facilities. Study findings suggest the utility of secondary data to assess 
treatment adaptation or switching for practical clinical trials. 
Although antipsychotics are effective for the treatment of schizophrenia, many patients do 
not respond to the first antipsychotic prescribed (1–3). Patients without a response on a second 
antipsychotic trial are typically considered treatment resistant (4–10). Because clozapine is the 
only antipsychotic proven effective for treatment-resistant schizophrenia, it is widely recognized 
as the preferred treatment option for patients who have not responded to two antipsychotic 
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monotherapy trials (4–10). This approach is reflected in evidence-based treatment guidelines, 
which recommend that such patients be offered clozapine (6–10). 
With these evidence-based treatment guidelines, one can conceptualize guideline-concordant 
treatment as an antipsychotic (AP) prescribing pathway, whereby AP1AP2clozapine. 
However, studies indicate that adherence to this guideline is low (11–25). Increasingly, long-
term use of two or more regularly scheduled antipsychotics (polypharmacy) is prescribed, often 
before clozapine (11,15,17–19,23–25). This practice is inconsistent with evidence-based 
guidelines, which do not endorse long-term antipsychotic polypharmacy and recommend it only 
as a last-line treatment when clozapine has failed (6–10). 
Rates of clozapine and antipsychotic polypharmacy use vary by treatment setting (11–25). 
However, most studies to date on antipsychotic prescribing have been cross-sectional even 
though longitudinal assessment is required to characterize appropriate use of polypharmacy. 
Cross-sectional studies cannot make the important distinction between antipsychotic 
polypharmacy use for treatment-resistant individuals (such as after a failed clozapine trial) and 
for other, less discriminating use. Also, findings from cross-sectional studies do not provide 
necessary information to assess which patients may be eligible for clozapine (11,16,20). This is 
of particular importance because the longitudinal studies that have been conducted indicate that 
clozapine is started after the failure of an average of six antipsychotic trials, including a period of 
antipsychotic polypharmacy, suggesting that the most effective treatment for treatment-resistant 
patients is delayed or not used (17–19,24,25). 
Longitudinal studies of large administrative data sets are becoming increasingly important. 
The development of more cost-efficient adaptive and practical clinical trials could be informed 
by data from existing sources. Also, studies examining the impact of policy or implementation 
strategies on prescribing pathways can be done in a naturalistic setting, guiding development of 
interventions that may be successful in real-world applications. Ultimately these studies may 
improve use of guideline-based treatment and outcomes in mental health. 
Therefore the goals of this descriptive retrospective cohort study were to use administrative 
data to develop a systematic method for describing longitudinal antipsychotic prescribing 
pathways and to describe the observed sequence of antipsychotic trials as related to evidence-
based guideline recommendations. 
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Methods 
Setting and data sources 
The Veterans Health Administration (VHA) is a national health care system treating >87,000 
veterans with schizophrenia or schizoaffective disorder  annually. Because the VHA has used 
electronic records for clinical care for many years, readily available administrative data sets can 
be used to identify and describe longitudinal antipsychotic prescribing pathways. Administrative 
data have been used extensively in other antipsychotic studies (11,20,26–28). 
We focused on 13 medical centers across two Veterans Affairs (VA) Integrated Service 
Networks (VISNs). We chose two VISNs in different regions of the United States that serve a 
large number of veterans with schizophrenia or schizoaffective disorder. Data to identify our 
target sample and characterize individuals’ medication history were obtained from the VA 
National Patient Care Database (NPCD), which contains information on inpatient and outpatient 
visits, ICD-9-CM diagnoses and procedure (CPT-4) codes, dispensed medication, and patient 
demographic characteristics. Data on average patient volume were derived from the fiscal year 
(FY) 2004 VA National Psychosis Registry (NPR) report, which includes data from multiple 
sources for all veterans treated for psychoses within the VHA. 
Study sample 
We identified all patients from two VISNs who received a prescription for an antipsychotic and 
were actively engaged in ongoing treatment, with a new episode of care for spectrum disorders in 
FY 2005. We focused on new episodes of care because treatment recommendations begin with 
the first treatment chosen for an episode of illness. 
A new episode of care was defined as an ICD-9-CM schizophrenia-related diagnosis (codes 
205.0–295.9) in at least one inpatient or two outpatient encounters in FY 2005, no schizophrenia-
related diagnosis in the previous two years, initiation of an index antipsychotic prescription, and 
no antipsychotic prescription for daily use >90 days in the year before the diagnosis. Patients 
with multiple psychiatric disorders coded on the diagnosis date were included if the number of 
schizophrenia-related diagnoses exceeded or equaled the number of other psychiatric disorders 
(20). Patients had to be actively engaged in VHA treatment, as evidenced by at least one VHA 
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outpatient visit for any medical or psychiatric disorder in both FY 2006 and FY 2007. The 
Boston VHA institutional review board approved this study. 
Antipsychotic use 
Antipsychotic use was defined as any dose of an antipsychotic (American Hospital Formulary 
Service class 28:16.08) for daily use dispensed from an outpatient VHA pharmacy for 90 days 
in FY 2005. The 90-day criterion was chosen on the basis of previous studies in which 
discontinuation of treatment due to adverse events versus inefficacy occurred earlier in treatment 
(25). 
The index antipsychotic prescription was defined as the first antipsychotic prescribed for 
daily use in FY 2005. To minimize the likelihood of falsely categorizing as polypharmacy 
transitions from one antipsychotic to another, we defined polypharmacy as concomitant 
prescription of two antipsychotics for daily use for >90 days (11). Intermittent exposures of 90 
days were considered noninformative. 
Informative sample 
Each patient’s prescribing pathway was characterized according to the antipsychotic trials 
received during the two years after the index antipsychotic trial. As summarized in Figure 1, 
receipt of a single antipsychotic other than clozapine for daily use (pathway 1) or two sequential 
prescriptions for regularly scheduled nonclozapine antipsychotics (pathway 2) with no gaps >90 
days for the duration of the study was categorized as monotherapy. Receipt of two prescriptions 
concomitantly for >90 days was categorized as polypharmacy. Antipsychotic polypharmacy 
could occur at various points in the treatment sequence (pathways 3–6). Patients who received 
clozapine for daily use as the second or third monotherapy trial were categorized as receiving 
early clozapine (pathway 8) or clozapine (pathway 7), respectively. Patients who received three 
or more sequential nonclozapine antipsychotics were categorized as delayed use of clozapine 
(pathway 9). Because prescription history data were available to definitively characterize 
pathways 1–9, we refer to them collectively as informative cases. 
Noninformative cases 
Some observed pathways were noninformative because incomplete information made a 
categorization ambiguous or uncertain. For example, some cases received a single trial (pathway 
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11) or sequential trials of antipsychotics (pathway 10) but no further antipsychotic prescriptions 
during the observation period. Thus it was not possible to characterize these pathways. 
Characterization of antipsychotic pathways 
Pathways 1, 2, and 7 represent guideline-endorsed antipsychotic prescribing pathways and thus 
were characterized as guideline concordant. In cases of extreme suicidality or aggression, 
guidelines endorse using clozapine as the second antipsychotic, so pathway 8 was categorized as 
guideline concordant (6). Pathways 3–6 all involved polypharmacy before clozapine was 
prescribed, and these pathways were categorized as guideline nonconcordant. Antipsychotic 
polypharmacy including clozapine was considered guideline nonconcordant because clozapine 
monotherapy was not used before polypharmacy was initiated. Pathway 9 involved use of a 
nonclozapine antipsychotic after two failed antipsychotic trials and was categorized as 
nonconcordant with guidelines. Pathways with clozapine as the first antipsychotic were excluded 
from the study because these likely reflect treatment-resistant patients for whom standard 
guideline-concordant care may not be appropriate. 
Analytic sample 
Previous studies have demonstrated that antipsychotic monotherapy and polypharmacy are the 
most common forms of antipsychotic treatment (12–14). These antipsychotic prescribing 
pathways also have the clearest relationship to guideline recommendations. Hence these groups 
formed the analytic sample and were used to address the second major aim of the study, 
comparison of prescribing practices with treatment guidelines. Because patients requiring 
clozapine treatment represent either more severely ill or treatment-resistant populations, they 
were excluded from the analytic sample. 
Measures and analyses 
Our measures and analyses proceeded at both the patient and facility center levels. At the patient 
level, our primary dependent variable was pathway assignment. Using the ICD-9-CM diagnosis 
codes associated with each medical encounter during the study, we created presence and absence 
variables for the antipsychotic-related comorbidities diabetes and hyperlipidemia. From the 
NPCD we obtained five demographic characteristics: age at time of the index visit, marital status 
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(four categories), gender, self-reported race (U.S. Census categories), and self-reported ethnicity 
(whether, yes-no, patients considered themselves Hispanic, Latino, or Spanish). 
We used basic frequencies, central tendency, and variance statistics to describe the number of 
cases in each of the antipsychotic pathway groups as well as the demographic and comorbidity 
profiles of all informative cases and the analytic sample. Within the analytic sample, we 
compared the demographic characteristics and distribution of comorbidities between 
monotherapy and polypharmacy groups by computing chi square statistics on the cross-
tabulation of antipsychotic pathway (monotherapy and polypharmacy) by those categorical 
variables. For age, we computed independent-groups t tests between monotherapy and 
polypharmacy. 
At the medical center level, we computed a polypharmacy rate as the percentage of cases in 
the analytic sample at that medical center that fell into the monotherapy and polypharmacy 
pathways. The denominator for this rate was the total number of cases in our analytic sample: the 
combined monotherapy and polypharmacy groups. As a measure of the total volume of patients 
with severe mental illness (psychotic and bipolar disorders), we obtained counts of such cases for 
each medical center from the NPR. Finally, because facilities were located in two geographically 
diverse VISNs, a dichotomous categorical location code was created to represent region 
(designated A or B). For analyses at the medical center level, we used basic descriptive statistics 
to describe the distribution of polypharmacy rates.  
To examine the association between polypharmacy rate and geographic region, we computed 
the median polypharmacy rate at the medical center level, classified facilities as above or below 
that rate, and computed the Fisher exact probability test on the cross-tabulation of polypharmacy 
rate (below or above median) by region. Finally, to examine the association between 
polypharmacy rate and volume of patients with severe mental illness, we computed the facility 
median for volume of these patients, classified facilities as being above or below that volume, 
and then computed the Fisher exact probability test on the cross-tabulation of polypharmacy rate 
(below or above median) and volume of patients with severe mental illness (below or above 
median). 
Results 
  
 
 
 
8 
 
We identified 1,923 new treatment episodes of schizophrenia and schizoaffective disorders in FY 
2005 and their distribution across nonredundant pathway groups (Table 1). Of the total, 310 
(16%) veterans did not utilize VHA outpatient services in FY 2006 and FY 2007. Another 338 
(18%) utilized VHA services but did not receive antipsychotic medications from an outpatient 
VHA pharmacy in FY 2005, and 272 (14%) did not receive a sufficient number of antipsychotic 
prescriptions to allow reasonable judgment about appropriate pathway assignment. These 920 
noninformative cases (48%) were not included in further analyses. There was no difference in 
median age between the informative and noninformative groups. 
The remaining 1,003 informative cases involved patients who entered a new treatment 
episode for schizophrenia or schizoaffective disorder, were treated with an antipsychotic in FY 
2005–FY 2007 and had one or more outpatient clinic visits in FY 2006 and FY 2007. Within the 
informative sample, 763 patients (76%) received care consistent with treatment guidelines (Table 
1). The most common guideline-concordant prescribing pathway was monotherapy (N=745, 
74%), followed by early use of clozapine (N=17, 2%). One patient received clozapine after two 
antipsychotic trials. The remaining 24% (N=240) of informative cases followed prescribing 
pathways that were nonconcordant with guidelines, with nonclozapine polypharmacy being the 
most common path (N=188, 19%). Notably, of patients receiving antipsychotic polypharmacy, 
65% (N=127) received polypharmacy as their first antipsychotic treatment and 4% (N=45) 
received polypharmacy in place of clozapine. 
A total of 933 informative cases (93%) qualified for the analytic sample, which for reasons 
discussed above consisted of the (nonclozapine) antipsychotic monotherapy (N=745) and 
(nonclozapine) polypharmacy (N=188) pathway groups. Self-reported race and ethnicity were 
missing in 49% and 51% of cases, respectively. The descriptive statistics for these variables and 
the chi square analyses were based, respectively, on persons whose race (N=474) or ethnicity 
(N=454) was known. The analytic sample was predominantly single (45%), Caucasian (54%), 
and male (93%) (Table 2), with a mean±SD age of 50.7±12.2. The incidence of diabetes and 
hyperlipidemia was 16% and 17%, respectively.  
There were no statistically significant associations between pathway group and demographic 
characteristics or comorbidities, with three exceptions. Six percent of the nonclozapine 
monotherapy sample was female compared with 13% of the nonclozapine polypharmacy group 
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(2=9.39, df=1, p<.01), and 52% of the monotherapy group was Caucasian compared with 65% 
of the polypharmacy group (2=8.54, df=3, p<.05). A significant association was observed with a 
higher proportion of hyperlipidemia in the polypharmacy group (22%) compared with the 
monotherapy group (15%; 2=4.38, df=1, p<.05). 
We observed a more than fourfold difference in antipsychotic polypharmacy rates between 
the medical centers (Figure 2). The median medical center polypharmacy rate was 21%, and the 
likelihood of being above that rate was no greater in region A compared with region B (p=.59, by 
Fisher exact test). The median annual medical center volume of cases of severe mental illness 
was 1,616, and the likelihood of being above or below the median polypharmacy rate for a 
facility was no greater at lower-volume facilities compared with higher-volume facilities (p=.10, 
by Fisher exact test). 
Discussion 
Using retrospective data of longitudinal antipsychotic prescribing, we classified 1,003 of 1,923 
patients (52%) with new treatment episodes of schizophrenia into one of 11 antipsychotic 
prescribing pathways. Of these informative cases, 74% were treated along antipsychotic 
monotherapy pathways, consistent with treatment guidelines. This is consistent with estimates 
that 70%–80% of patients with schizophrenia are responsive to treatment (1,2). 
We found that 24% of patients received care nonconcordant with guidelines, primarily 
involving antipsychotic polypharmacy. A total of 13% of informative cases received 
polypharmacy before receiving a monotherapy antipsychotic trial. This rate is 3.5 times higher 
than previously reported in the California Medicaid population (29). This discrepancy is most 
likely related to methodological differences. Whereas the Medicaid study reported antipsychotic 
polypharmacy as the initial treatment for patients who received prescriptions for two 
antipsychotics at the first fill, our study defined polypharmacy as initial treatment when patients 
did not receive an adequate monotherapy trial of antipsychotic before receiving antipsychotic 
polypharmacy. Thus, for our population, initial treatment with antipsychotic polypharmacy 
included patients who received polypharmacy within the first 90 days of treatment. The fact that 
65% of patients treated with polypharmacy started antipsychotic polypharmacy within the first 
90 days of treatment indicates that a majority of patients on polypharmacy were not treated with 
a single evidence-based treatment. In summary, both studies suggest that antipsychotic 
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polypharmacy is often being used as the initial treatment, contravening all evidence-based 
guidelines. 
Similar to other studies, our study showed a significant difference among medical centers in 
utilization of antipsychotic polypharmacy, and this variability was not associated with 
geographic region or volume of patients with severe mental illness. Previous studies indicated 
that clinicians reserve antipsychotic polypharmacy for patients with more severe illness. 
However, it seems unlikely there would be a fourfold difference in the number of severely ill 
patients between facilities and that 65% of patients receiving polypharmacy were so sick that 
they required antipsychotic polypharmacy as first-line treatment (30). Thus future research 
should investigate whether organizational characteristics account for some variability in 
antipsychotic prescribing. For example, differences in availability of resources, staffing, quality 
improvement capability, program implementation, care coordination, and communication may 
affect provision of care (26,31–33). The organization and provision of care have been shown to 
vary among VHA mental health programs, which may contribute to the observed variation 
(31,33). 
Medical centers with lower volume of patients with severe mental illness trended toward 
higher rates of polypharmacy. Whereas five of six low-volume medical centers had higher rates 
of polypharmacy, five of seven high-volume medical centers had lower rates of polypharmacy, 
suggesting that more experience with severe mental illness may be related to increased 
adherence with treatment guidelines. 
Clozapine underutilization is an issue in the treatment of schizophrenia and schizoaffective 
disorders, possibly because of increased prescribing burden, including prescriber and patient 
registration requirements; significant side-effect burden; and frequent laboratory testing to 
monitor for side effects. In this study, only about 2% (N=18) of patients in the informative 
sample received clozapine consistent with evidence based guidelines, whereas 45 patients who 
fared poorly on two antipsychotic trials did not receive clozapine. Some of these cases may 
reflect antipsychotic intolerance rather than clozapine nonresponse. However, given that up to 
20% of patients with schizophrenia are treatment resistant whereas under 2% of patients received 
clozapine and almost 19% received antipsychotic polypharmacy, it seems unlikely that use of 
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clozapine is optimized. It is concerning that patients may be receiving polypharmacy in place of 
clozapine or that initiation of clozapine is delayed. 
Consistent with other studies, receipt of antipsychotic polypharmacy was more common with 
women and Caucasian patients (29,34). Our finding that patients receiving antipsychotic 
polypharmacy were more likely to have hyperlipidemia is contrary to at least one previous study 
(35). However, antipsychotic polypharmacy may be a marker for factors such as body mass 
index and concomitant medications that were not controlled for in this study. 
It is interesting to note that 338 patients diagnosed as having schizophrenia or schizoaffective 
disorder received care within the VHA but did not receive antipsychotics. Some of these patients 
may fill their prescriptions outside the VHA. It is also possible that these patients had less severe 
illness or chose not to fill antipsychotic prescriptions and therefore represent a population in need 
of outreach. 
Conclusions 
To our knowledge, this study is unique in its description and categorization of antipsychotic 
prescribing pathways. Our method allowed for identification of justified deviations from 
treatment guidelines and of patients possibly eligible for a clozapine trial. Nonetheless, there are 
some limitations that should be noted. Data derived from prescription files do not account for 
nonadherent patients, and the filling of a prescription does not necessarily mean that the 
medications were taken how and when they should have been. Given that this study did not focus 
on treatment outcomes, however, this limitation is not a critical concern. Also, such data cannot 
account for patient and clinician preferences. Medication changes may have been secondary to 
drug intolerance rather than inefficacy, and thus all 45 patients with two unsuccessful sequential 
trials of monotherapy may not have been appropriate for a clozapine trial. However, the use of 
the 90-day minimum to identify an antipsychotic trial in this study makes this somewhat less 
likely. 
Consistent with prior cross-sectional analyses, we observed that 19% of patients with 
schizophrenia treated within the VHA received polypharmacy, and the utilization of clozapine 
was several-fold lower. A large portion of patients started with polypharmacy as the initial 
antipsychotic trial. In addition, there was unexplained variability between medical centers in use 
of antipsychotic polypharmacy. Future research should consider the causes of variability and its 
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impact on patient outcomes. Pathways analysis is a useful way to use secondary data to inform 
practical clinical trials and effectiveness of prescribing policies. 
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Figure 1 Antipsychotic (AP) prescribing pathways among veterans with schizophrenia or schizoaffective disorder
a 
 
 
a
Guideline-concordant pathways are in boldface. 
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Figure 2 Rates of polypharmacy for treatment of schizophrenia or schizoaffective disorder, by 
VHA facility
a 
 
 
a
N indicates the facility denominator of total analytic sample cases. VHA, Veterans Health 
Administration 
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Table 1 Observed distribution of antipsychotic prescribing pathways for VHA patients with 
schizophrenia or schizoaffective disorder
a
 
Pathway N 
% total 
cases 
(N=1,923) 
% informative 
cases 
(N=1,003) 
Informative cases    
 Concordant with guidelines    
  Monotherapy without clozapine 745 39 74 
  Early use of clozapine 17 1 2 
  Clozapine 1 <1 <1 
  Subtotal 763 40 76 
 Nonconcordant with guidelines    
  Polypharmacy without clozapine 188 10 19 
  Polypharmacy with  clozapine 7 <1 <1 
  Delayed use of clozapine 45 2 5 
  Subtotal 240 13 24 
 Total 1,003 52 100 
Noninformative cases    
 Insufficient VHA antipsychotic trials 272 14  
 No VHA utilization 310 16  
 VHA utilization but no antipsychotics 
dispensed 
338 18  
 Total 920 48  
Total 1,923 100  
a
 VHA, Veterans Health Administration 
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Table 2 Demographic and clinical characteristics of VHA patients with schizophrenia or 
schizoaffective disorder
a
  
Characteristic 
Total analytic sample  
(N=933) 
Nonclozapine 
monotherapy  
(N=745) 
Nonclozapine 
polypharmacy  
(N=188) 
N % N % N % 
Caucasian 258 54 193 52 65 65 
Hispanic 50 11 36 10 14 15 
Male 863 93 699 94 164 87 
Not married 417 45 332 45 85 46 
Comorbidity
b
       
 Diabetes 152 16 123 17 29 15 
 Hyperlipidemia 156 17 115 15 41 22 
a
VHA, Veterans Health Administration. Because of missing data, the denominator for percentages is not the group 
maximum for all variables. 
b
Patients may appear in more than one category. 
